Radium-223 dichloride in clinical practice

a review

Luigia Florimonte, Luca Dellavedova, Lorenzo Stefano Maffioli

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)1896-1909
Number of pages14
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume43
Issue number10
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Radium
Radiopharmaceuticals
Disease Progression
Prostatic Neoplasms
Samarium
Neoplasm Metastasis
Bone and Bones
Pain
Strontium
Castration
Diphosphonates
Osteoclasts
Therapeutics
Radioisotopes
Immunotherapy
Androgens
Analgesics
Radiotherapy
Neoplasms

Keywords

  • Bone metastasis
  • Overall survival
  • Radium-223 dichloride
  • α-Emitters

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radium-223 dichloride in clinical practice : a review. / Florimonte, Luigia; Dellavedova, Luca; Maffioli, Lorenzo Stefano.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43, No. 10, 01.09.2016, p. 1896-1909.

Research output: Contribution to journalReview article

Florimonte, Luigia ; Dellavedova, Luca ; Maffioli, Lorenzo Stefano. / Radium-223 dichloride in clinical practice : a review. In: European Journal of Nuclear Medicine and Molecular Imaging. 2016 ; Vol. 43, No. 10. pp. 1896-1909.
@article{3c1824058bc24551a446c592dc054ef2,
title = "Radium-223 dichloride in clinical practice: a review",
abstract = "The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.",
keywords = "Bone metastasis, Overall survival, Radium-223 dichloride, α-Emitters",
author = "Luigia Florimonte and Luca Dellavedova and Maffioli, {Lorenzo Stefano}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s00259-016-3386-5",
language = "English",
volume = "43",
pages = "1896--1909",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "10",

}

TY - JOUR

T1 - Radium-223 dichloride in clinical practice

T2 - a review

AU - Florimonte, Luigia

AU - Dellavedova, Luca

AU - Maffioli, Lorenzo Stefano

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.

AB - The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.

KW - Bone metastasis

KW - Overall survival

KW - Radium-223 dichloride

KW - α-Emitters

UR - http://www.scopus.com/inward/record.url?scp=84982730476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982730476&partnerID=8YFLogxK

U2 - 10.1007/s00259-016-3386-5

DO - 10.1007/s00259-016-3386-5

M3 - Review article

VL - 43

SP - 1896

EP - 1909

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 10

ER -